TGTX
Income statement / Annual
Last year (2024), TG Therapeutics, Inc.'s total revenue was $329.00 M,
an increase of 40.80% from the previous year.
In 2024, TG Therapeutics, Inc.'s net income was $23.38 M.
See TG Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$329.00 M |
$233.66 M |
$2.79 M |
$6.69 M |
$152.00 K |
$152.00 K |
$152.00 K |
$152.38 K |
$152.38 K |
$152.38 K |
| Cost of Revenue |
$38.49 M
|
$14.13 M
|
$265.00 K
|
$790.00 K
|
$0.00
|
$0.00
|
$88.00 K
|
$82.36 K
|
$62.96 K
|
$0.00
|
| Gross Profit |
$290.52 M
|
$219.53 M
|
$2.52 M
|
$5.90 M
|
$152.00 K
|
$152.00 K
|
$64.00 K
|
$70.03 K
|
$89.42 K
|
$152.38 K
|
| Gross Profit Ratio |
0.88
|
0.94
|
0.9
|
0.88
|
1
|
1
|
0.42
|
0.46
|
0.59
|
1
|
| Research and Development Expenses |
$94.29 M
|
$76.19 M
|
$125.35 M
|
$222.58 M
|
$165.90 M
|
$154.18 M
|
$153.79 M
|
$96.89 M
|
$66.49 M
|
$43.45 M
|
| General & Administrative Expenses |
$154.30 M
|
$122.71 M
|
$95.48 M
|
$128.09 M
|
$107.85 M
|
$15.03 M
|
$15.16 M
|
$16.33 M
|
$9.89 M
|
$15.63 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$154.30 M
|
$122.71 M
|
$95.48 M
|
$128.09 M
|
$107.85 M
|
$15.03 M
|
$15.16 M
|
$16.33 M
|
$9.89 M
|
$15.63 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$61.00 K
|
-$58.74 K
|
$393.20 K
|
$1.03 M
|
| Operating Expenses |
$248.59 M
|
$198.90 M
|
$220.84 M
|
$350.67 M
|
$273.75 M
|
$169.21 M
|
$174.55 M
|
$118.86 M
|
$79.12 M
|
$63.33 M
|
| Cost And Expenses |
$287.08 M
|
$213.03 M
|
$221.10 M
|
$351.46 M
|
$273.75 M
|
$169.21 M
|
$174.55 M
|
$118.86 M
|
$79.12 M
|
$63.33 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$857.00 K
|
$294.48 K
|
$323.03 K
|
$174.65 K
|
| Interest Expense |
$24.03 M
|
$12.62 M
|
$10.19 M
|
$5.64 M
|
$6.33 M
|
$5.29 M
|
$1.73 M
|
$1.14 M
|
$0.00
|
$972.74 K
|
| Depreciation & Amortization |
$280.00 K
|
$423.00 K
|
$515.00 K
|
$494.00 K
|
$374.00 K
|
$282.00 K
|
$88.00 K
|
$82.36 K
|
$62.96 K
|
$15.45 K
|
| EBITDA |
$49.90 M |
$26.10 M |
-$213.11 M |
-$341.97 M |
-$272.68 M |
-$167.30 M |
-$173.39 M |
-$118.39 M |
-$78.91 M |
-$63.16 M |
| EBITDA Ratio |
0.15
|
0.11
|
-76.52
|
-51.12
|
-1793.93
|
-1100.67
|
-1140.75
|
-776.96
|
-517.82
|
-414.52
|
| Operating Income Ratio |
0.13
|
0.09
|
-78.39
|
-51.54
|
-1799.96
|
-1112.2
|
-1147.37
|
-779.05
|
-518.23
|
-414.62
|
| Total Other Income/Expenses Net |
-$16.34 M
|
-$7.57 M
|
-$5.50 M
|
-$3.33 M
|
-$5.79 M
|
-$3.82 M
|
$918.00 K
|
$235.99 K
|
$716.00 K
|
$231.37 K
|
| Income Before Tax |
$25.59 M
|
$13.06 M
|
-$223.81 M
|
-$348.10 M
|
-$279.38 M
|
-$172.87 M
|
-$173.48 M
|
-$118.48 M
|
-$78.25 M
|
-$62.95 M
|
| Income Before Tax Ratio |
0.08
|
0.06
|
-80.36
|
-52.04
|
-1838.03
|
-1137.31
|
-1141.33
|
-777.5
|
-513.53
|
-413.1
|
| Income Tax Expense |
$2.21 M
|
$390.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$918.00 K
|
-$235.74 K
|
-$716.23 K
|
-$231.37 K
|
| Net Income |
$23.38 M
|
$12.67 M
|
-$223.81 M
|
-$348.10 M
|
-$279.38 M
|
-$172.87 M
|
-$173.48 M
|
-$118.48 M
|
-$78.25 M
|
-$62.95 M
|
| Net Income Ratio |
0.07
|
0.05
|
-80.36
|
-52.04
|
-1838.03
|
-1137.31
|
-1141.33
|
-777.5
|
-513.53
|
-413.1
|
| EPS |
0.16 |
0.0893 |
-1.46 |
-2.63 |
-2.42 |
-1.96 |
-2.3 |
-1.91 |
-1.6 |
-1.38 |
| EPS Diluted |
0.15 |
0.0853 |
-1.46 |
-2.63 |
-2.42 |
-1.96 |
-2.3 |
-1.91 |
-1.6 |
-1.38 |
| Weighted Average Shares Out |
$145.32 M
|
$141.96 M
|
$135.41 M
|
$132.22 M
|
$115.33 M
|
$88.37 M
|
$75.47 M
|
$62.07 M
|
$49.04 M
|
$45.65 M
|
| Weighted Average Shares Out Diluted |
$160.34 M
|
$148.51 M
|
$135.41 M
|
$132.22 M
|
$115.33 M
|
$88.37 M
|
$75.47 M
|
$62.07 M
|
$49.04 M
|
$45.65 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
